Skip to main content
Aspire Biopharma Holdings, Inc. logo

Aspire Biopharma Holdings, Inc. — Investor Relations & Filings

Ticker · ASBP ISIN · KYG7207P1110 LEI · 529900UC0AFER5IEH285 US Manufacturing
Filings indexed 197 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US ASBP

About Aspire Biopharma Holdings, Inc.

https://www.powerupacq.com/

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company that develops and markets novel sublingual drug delivery technologies. The company's platform aims to enhance existing FDA-approved medications and nutraceuticals by creating needle-free, under-the-tongue formulations. Its development pipeline includes a sublingual version of aspirin, a needle-free semaglutide for diabetes and weight management, and a rapid-acting erectile dysfunction medication. Aspire is also exploring applications for its technology in areas such as anti-nausea, anti-psychotic, and seizure treatments.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K
Regulatory Filings
2026-05-14 English
DEF 14A - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
Proxy Solicitation & Information Statement
2026-05-11 English
8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
Regulatory Filings
2026-04-20 English
8-K/A - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
Regulatory Filings
2026-04-17 English
8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)
Regulatory Filings
2026-04-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.